Synthesis, Spectral Characterization, and In Vitro Cellular Activities of Metapristone, a Potential Cancer Metastatic Chemopreventive Agent Derived from Mifepristone (RU486)
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 2
Abstract
Mifepristone (RU486) is marketed and used widely by women as an abortifacient, and experimentally for psychotic depression and anticancer treatments. After administration, metapristone is found to be the most predominant metabolite of mifepristone. We hypothesized that adhesion of circulating tumor cells (CTCs) to vascular endothelial bed is a crucial starting point in metastatic cascade, and that metapristone can serve as a cancer metastatic chemopreventive agent that can interrupt adhesion and invasion of CTCs to the intima of microvasculature. In the present study, we modified the synthesis procedure to produce grams of metapristone, fully characterized its spectral properties and in vitro cellular activities, including its cytostatic effects, cell cycle arrest, mitochondrial membrane potential, and apoptosis on human colorectal cancer HT-29 cells. Metapristone concentration dependently interrupted adhesion of HT-29 cells to endothelial cells. Metapristone may potentially be a useful agent to interrupt metastatic initiation.
Authors and Affiliations
Jichuang Wang, Jianzhong Chen, Liyuan Wan, Jingwei Shao, Yusheng Lu, Yewei Zhu, Minrui Ou, Suhong Yu, Haijun Chen, Lee Jia
Keywords
Related Articles
- EP ID EP681063
- DOI 10.1208/s12248-013-9559-2
- Views 33
- Downloads 0
A Hybrid Markov Chain–von Mises Density Model for the Drug-Dosing Interval and Drug Holiday Distributions
The online version of this article (doi:10.1208/s12248-014-9713-5) contains supplementary material, which is available to authorized users.
Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication
We evaluated a new approach to AIDS therapy by using combinations of oligodeoxynucleotides (ODNs), delivered with a lipid-based carrier system, that target different HIV viral genome sites. We identified some of the fact...
Immunogenicity of Subcutaneously Administered Therapeutic Proteins—a Mechanistic Perspective
The administration of therapeutic proteins via the subcutaneous route (sc) is desired for compliance and convenience, but could be challenging due to perceived immunogenic potential or unwanted immune responses. There ar...
Influence of P-Glycoprotein Inhibition or Deficiency at the Blood–Brain Barrier on 18F-2-Fluoro-2-Deoxy-d -glucose (18F-FDG) Brain Kinetics
The fluorinated d -glucose analog 18F-2-fluoro-2-deoxy-d -glucose (18F-FDG) is the most prevalent radiopharmaceutical for positron emission tomography (PET) imaging. P-Glycoprotein’s (P-gp, MDR1, and ABCB1) funct...
Ligand-Binding Assay Development: What Do You Want to Measure Versus What You Are Measuring?
The analysis of biotherapeutics by ligand-binding assay (LBA) is associated with some unique challenges that are unlike those commonly encountered in chromatographic methods for chemically based small molecule drugs. Whi...